ArticleCancer causes & control : CCC2018
Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
Article in Cancer causes & control : CCC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Factors associated with shorter-interval cervical cancer screening for young women in three United States healthcare systems.Preventive medicine reports · 2023Article
- Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Trends and Racial/Ethnic Differences in Predictors of Cervical Cancer Screening among US Women Ages 30-64 Years.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Cervical cancer screening compliance among active duty service members in the US military.Preventive medicine reports · 2022Article
- Cervical cancer screening in high-altitude areas in China: A large cross-section study of 25,173 women in northern Tibet.Frontiers in oncology · 2022Article
- Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics.Preventive medicine · 2022Article
- De-implementation of cervical cancer screening before age 21.Preventive medicine · 2021Article
- Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.Gynecologic oncology · 2021Article
- Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.Gynecologic oncology · 2021Article
- Revisiting time to translation: implementation of evidence-based practices (EBPs) in cancer control.Cancer causes & control : CCC · 2021Article
- Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results.Journal of lower genital tract disease · 2020Article
- Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.British journal of cancer · 2019Article
- Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.MMWR. Morbidity and mortality weekly report · 2019Article
- Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.Journal of women's health (2002) · 2019Article
- Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women.BMC women's health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the adoption of HPV testing and recommended extended cervical cancer screening intervals in clinical practice, we described yearly uptake of Pap/HPV cotesting and estimated length of time between normal screens by patient characteristics.
methodsWe examined 55,575 Pap/HPV records from 27,035 women aged 30-65 years from the Johns Hopkins Hospital Pathology Data System between 2006 and 2013. Cotest uptake and median times to next screening test for cotests and cytology only were calculated. Adjusted hazard ratios were estimated using Cox proportional hazards models, with random effects adjustment for clustering within clinic.
resultsCotest usage increased from < 10% in 2006 to 78% in 2013. The median time to next screening test following normal cytology alone remained constant around 1.5 years. Screening intervals following a dual-negative cotest increased from 1.5 years in 2006/2007 to 2.5 years in 2010, coincident with increases in the proportion of women cotested. Intervals following a dual negative cotest were longer among Medicare patients (3 years) compared with privately insured women (2.5 years), and shorter among black (2 years) compared with white women (2.8 years).
conclusionBy mid-2013 we observed broad adoption of Pap/HPV cotesting in routine screening in a large academic medical center. Increased screening intervals were observed only among cotested women, while those screened by cytology alone continued to be screened almost annually. The influence of different combinations of race and insurance on screening intervals should be further evaluated to ensure balance of screening risks and benefits in the U.S. POPULATION:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.